Artificial Intelligence in Drug Discovery Market By Technology (Machine Learning, Deep Learning), Application (Endocrinology, Cardiology, Oncology), End-User (Pharmaceutical & Biotechnological Companies, Government Agencies), & Region for 2024-2031

Artificial Intelligence in Drug Discovery Market Valuation - 2024-2031

The growing demand for artificial intelligence (AI) in drug discovery, the conventional drug discovery approach is time-consuming and costly, with a high failure rate. AI can significantly speed up this process by automating operations like target selection, lead optimization, and clinical trial analysis. The complexity of diseases, combined with the desire for individualized treatments, has boosted demand for novel drug discovery procedures. The market size surpass USD 1.74 Billion valued in 2024 to reach a valuation of around USD 3.09 Billion by 2031.

AI can aid in the analysis of massive volumes of biological and clinical data in order to identify new drug targets and design more effective treatments. AI can help to develop treatments for neglected diseases by assessing existing data and discovering potential repurposing opportunities. The rising demand for cost-effective and efficient artificial intelligence in drug discovery is enabling the market grow at a CAGR of 8.25% from 2024 to 2031.

Artificial Intelligence in Drug Discovery Market: Definition/ Overview

Artificial intelligence (AI) in drug discovery is the use of machine learning algorithms and computer approaches to streamline and improve the processes involved in discovering and producing new medications. AI can anticipate how different chemicals will interact with targets in the body, find possible drug candidates, and optimize their efficacy and safety profiles by analyzing massive datasets from biological, chemical, and clinical sources. This method reduces the usual drug discovery schedule, which can take years or even decades, allowing researchers to rapidly iterate on viable remedies and bring effective therapies to market faster.

AI in drug development appears to be promising, as machine learning, deep learning, and data analytics advance. As more extensive datasets become available, ranging from genomes to electronic health records, AI's capacity to identify novel therapeutic targets and customize treatments will improve. Regulatory organizations are starting to identify and utilize AI approaches, paving the path for further acceptance and integration in pharmaceutical research and development.

The growing demand for efficient and cost-effective drug discovery processes indicates that AI will play a critical role in revolutionizing how new therapies are developed, potentially leading to breakthroughs in treating complex diseases such as cancer, neurodegenerative disorders, and rare genetic conditions.

What are the Factors that Surge the Demand for Artificial Intelligence in the Drug Discovery Market?

The increasing R&D costs in the pharmaceutical industry will have a substantial impact on the artificial intelligence in drug discovery market. As the average cost of producing a new drug, which was assessed at USD 2.6 Billion in 2016 research, continues to grow, pharmaceutical companies are looking for ways to improve efficiency and reduce costs. Adoption of AI technologies provide a solution by expediting the drug discovery process, allowing for speedier identification of viable candidates while also lowering development time and resources. This financial pressure, combined with the need for novel solutions, is driving the incorporation of AI into drug discovery, making it a major priority for the firm.

The growing number of drug discovery collaborations will fuel the artificial intelligence in drug discovery market. Collaborations increased by 40% between 2019 and 2020, indicating that the pharmaceutical industry recognizes the benefits of AI technologies in optimizing medication development. These collaborations allow for the sharing of expertise and resources, resulting in more effective and efficient drug discovery processes, expediting the development of new therapeutics and driving market growth.

What are the Factors that Hamper the Growth of Artificial Intelligence in the Drug Discovery Market?

Data privacy and accessibility concerns may hinder the growth of the artificial intelligence in drug discovery market. AI relies largely on large datasets to train algorithms and improve predicted accuracy, tight data privacy restrictions may limit access to critical medical information and biological data. Data sharing standards vary by area, which can create impediments to collaboration between pharmaceutical companies and AI firms.

The integration of AI into traditional drug development methodologies may hamper the growth of the artificial intelligence in drug discovery market. Many pharmaceutical organizations are entrenched in traditional procedures and may be hesitant to employ AI technologies due to the perceived risks and uncertainty. The hesitation can postpone the move to more innovative, AI-driven techniques, limiting AI's overall ability to improve efficiency and reduce expenses in drug development.

Category-Wise Acumens

Which Factors Boost the Use of Artificial Intelligence in Drug Discovery Market?

The deep learning segment is currently dominating the artificial intelligence (AI) in drug discovery market. Drug discovery acceleration will boost the deep learning segment of the artificial intelligence in drug discovery market. Deep learning algorithms excel at processing large, complicated datasets, allowing for faster and more accurate predictions of medication interactions and efficacy. As the pharmaceutical sector strives to decrease the lengthy schedules associated with traditional drug development methods.

Traditional deep learning approaches are projected to drive the artificial intelligence in drug discovery market by improving data analysis and model training. These well-established algorithms, such as neural networks, have proven to be successful at digesting complicated biological data, allowing for more accurate predictions in drug discovery.

Which Factors Expand the Use of Artificial Intelligence in Drug Discovery Market?

The oncology segment is currently leading the artificial intelligence (AI) drug discovery market. Cancer is a difficult disease with a high unmet medical need, and artificial intelligence has the potential to significantly accelerate the development of new therapies. AI-powered systems can process massive volumes of genomic data, discover new therapeutic targets, and optimize medication prospects. AI can help tailor cancer treatment by predicting patient responses to various medicines.

Neurological diseases, such as Alzheimer's and Parkinson's, are difficult to treat due to their complicated pathology. AI can assist researchers in understanding the underlying causes of many disorders, identifying novel therapeutic targets, and developing more effective treatments. Furthermore, AI can help with the diagnosis and prognosis of neurological diseases, hence enhancing patient care.

Will the Leading Pharmaceutical Companies in the North American Region Propel the Artificial Intelligence in Drug Discovery Market?

The North America region is currently dominating the artificial intelligence (AI) in drug discovery market. The presence of major pharmaceutical corporations in the North American region will propel the artificial intelligence in drug discovery market. These companies are progressively utilizing AI technologies to better medication discovery and development procedures, hence significantly contributing to market expansion. Government initiatives, such as the FDA's support for AI technologies and the NIH's funding of around USD 50 Million for AI-related research, help to accelerate this expansion. According to a 2023 poll, 72% of North American pharmaceutical and biotech companies are either employing or plan to utilize AI in their drug research activities.

The favorable regulatory environment in North America will drive the artificial intelligence in drug discovery market. The US Food and Drug Administration (FDA) has actively supported AI technology through its "AI/ML-Based Software as a Medical Device (SaMD) Action Plan," which has approved many AI-based medical devices. According to Deloitte research, 75% of large pharmaceutical companies would employ AI-driven drug development platforms by 2025, assisted by the favorable regulatory framework. The National Institutes of Health (NIH) raised funding for AI research by 25% in 2023, while the 21st Century Cures Act encouraged sophisticated analytics in medication development. According to a 2023 poll, 68% of North American biotech firms believe the regulatory framework is positive.

Will the Government Initiatives in Asia Pacific Region Lead the Artificial Intelligence in Drug Discovery Market?

The Asia-Pacific region is emerging as the fastest-growing segment within the AI drug discovery market. Government initiatives in the Asia Pacific region are driving the growth of the AI in drug discovery market, with significant investments made in AI research and development. According to the Asia Pacific Economic Cooperation (APEC), these investments are estimated to total $58 billion by 2025, with considerable amounts going toward healthcare and drug discovery. Japan allocates USD 1 Billion per year through its "AI Strategy 2019," while South Korea intends to invest USD 2 Billion by 2025, allocating 30% of its drug development fund to AI. India's National Strategy for Artificial Intelligence seeks USD 1 Billion in yearly investment by 2025 to assist multiple AI-driven enterprises. According to a poll conducted by the Asian Development Bank, 65% of regional pharmaceutical companies believe that government actions have boosted AI use.

Rising healthcare spending in the Asia Pacific region is predicted to considerably boost the growth of the AI in Drug Discovery market, mirroring trends in North America. Healthcare expenses in the region are rising due to a growing population and an increasing frequency of chronic diseases, necessitating the use of modern technologies such as AI to improve efficiency and cut costs in drug research. The pharmaceutical business is progressively incorporating AI, as indicated by a Deloitte poll that found that a significant proportion of executives believe AI can significantly reduce drug research schedules and costs.

Competitive Landscape

The artificial intelligence in drug discovery market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the market include:

• Accelrys Software, Inc.
• Allergan plc
• Bayer AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Roche Holding AG
• Sanofi SA

Latest Developments

• In May 2024, Google DeepMind launched the third iteration of their AlphaFold AI-based model, which aims to improve medicine design and disease targeting. Researchers at DeepMind and Isomorphic Labs can now trace the behavior of all molecules, including human DNA, with this latest edition.
• In April 2024, Xaira Therapeutics, an AI-powered medication discovery and development startup, raised more than USD 1 Million in a combined fundraising round with ARCH Venture Partners and Foresite Labs. The startup uses machine learning, data creation algorithms, and therapeutic product development to target previously difficult pharmacological targets.

Artificial Intelligence in Drug Discovery Market, By Category

• Technology:
• Machine Learning
• Deep Learning
• Natural Language Processing
• Application:
• Endocrinology
• Cardiology
• Oncology
• Neurology
• End-User:
• Pharmaceutical & Biotechnological Companies
• Academic & Research Institutes
• Government Agencies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa